↓ Skip to main content

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, September 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
4 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma
Published in
Journal of Experimental & Clinical Cancer Research, September 2022
DOI 10.1186/s13046-022-02490-3
Pubmed ID
Authors

Qiu Tu, Xiuyun Liu, Xiaoqing Yao, Ruixue Li, Gaojing Liu, Honglv Jiang, Kaiqin Li, Qiongfang Chen, Xiaoyan Huang, Qing Chang, Guoqiang Xu, Hong Zhu, Peng Shi, Bo Zhao

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 13%
Researcher 1 13%
Student > Doctoral Student 1 13%
Unknown 5 63%
Readers by discipline Count As %
Medicine and Dentistry 2 25%
Biochemistry, Genetics and Molecular Biology 1 13%
Unknown 5 63%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2022.
All research outputs
#2,985,785
of 25,394,764 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#131
of 2,384 outputs
Outputs of similar age
#60,696
of 432,265 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#6
of 71 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,384 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 432,265 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.